VeriMomHIGH RISK
¿Debo evitar minoxidil succinoyl oligopeptide-143 durante el embarazo? | VeriMom
Reviewed by VeriMom Editorial Team · Last reviewed
What to use instead
Pregnancy-safe ingredients that serve a similar function:
Pregnancy-safe products to use instead
Products built around the safer ingredients above, scored "no known risks" or "low risk".
Mew mew tweet
100Mew mew tweet Cedar Spruce Baking Soda Free
Avero
100Avero Solid Deodorant
L'Occitane
100L´Occitane Powder To-mousse Facial Exfoliator
Unknown
100schmidts here now
Sustain Yourself
100Sustain Yourself Natural Deodorant
Bitamin
100Bitamin Natural Deodorant N'orange
Gilette
99Gilette Intimate Anti-chafing Stick
Dr Teals's
99Dr Teals's Aluminum Free Deodorant Charcoal
HappySoaps
99Happysoaps Neutraal
900care
99Déodorant stick parfum embruns
Sources & references
Authoritative references used to score this ingredient.
Alternativas seguras a minoxidil succinoyl oligopeptide-143 en el embarazo | VeriMom
Ingredientes — Ingredientes
Ver también
FAQ
- ¿Es minoxidil succinoyl oligopeptide-143 seguro durante el embarazo?
- Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.
- ¿Es minoxidil succinoyl oligopeptide-143 seguro durante la lactancia?
- Minoxidil is a pharmacologically active systemic agent with reports of infant effects after maternal topical use and some evidence of transmission/infant exposure; regulatory guidance warns about infant hypertrichosis following skin contact. Thus breastfeeding safety is a concern (h=2). Mechanistic concern is demonstrated systemic exposure; measured transfer into milk is not well-quantified in public cosmetic dossiers, so exposure is graded as low but measurable for breastfeeding (e=1).
- ¿Es minoxidil succinoyl oligopeptide-143 seguro para la piel del bebé?
- For dermal contact with infants (0–3 yr) there are case reports of excessive hair growth in infants after parental topical minoxidil use/contact, and infants have higher dermal uptake (immature barrier and higher surface-area-to-weight). Therefore hazard and mechanism scores follow minoxidil (h=2, m=2) and exposure is increased (adult e=2 → infant e=3 per your rules). No infant-specific toxicology studies for the peptide were found; the concern is driven by the minoxidil parent compound and case reports.
- ¿Cómo puntúa VeriMom a minoxidil succinoyl oligopeptide-143?
- VeriMom puntúa minoxidil succinoyl oligopeptide-143 en 33/100 (riesgo alto) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a minoxidil succinoyl oligopeptide-143 en el embarazo?
- Consulta nuestra lista de alternativas seguras a minoxidil succinoyl oligopeptide-143 según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.